Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer

[1]  M. Dowsett,et al.  Inactivating NF1 Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance , 2019, Clinical Cancer Research.

[2]  L. Saal,et al.  Whole-genome-sequencing of triple negative breast cancers in a population-based clinical study , 2019, Nature Medicine.

[3]  G. Shapiro,et al.  PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer. , 2019, Cancer discovery.

[4]  I. Kozarewa,et al.  Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  A. Jager,et al.  Direct Ex Vivo Observation of Homologous Recombination Defect Reversal After DNA-Damaging Chemotherapy in Patients With Metastatic Breast Cancer. , 2019, JCO precision oncology.

[6]  A. Ashworth,et al.  PARP inhibition enhances tumor cell–intrinsic immunity in ERCC1-deficient non–small cell lung cancer , 2019, The Journal of clinical investigation.

[7]  A. Harris,et al.  BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors , 2018, bioRxiv.

[8]  C. Caldas,et al.  A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation , 2018, EMBO molecular medicine.

[9]  W. Eiermann,et al.  Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation , 2018, The New England journal of medicine.

[10]  Paul Ellis,et al.  Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial , 2018, Nature Medicine.

[11]  P. Kristel,et al.  RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  M. Koehler,et al.  Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer , 2018, Nature Communications.

[13]  N. Turner.  Signatures of DNA‐Repair Deficiencies in Breast Cancer , 2017, The New England journal of medicine.

[14]  W. Foulkes,et al.  Olaparib for Metastatic Germline BRCA-Mutated Breast Cancer. , 2017, The New England journal of medicine.

[15]  Alain Viari,et al.  Whole-Genome Sequencing Reveals Breast Cancers with Mismatch Repair Deficiency. , 2017, Cancer research.

[16]  E. Lander,et al.  A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer , 2017, Nature Genetics.

[17]  M. Robson,et al.  Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation , 2017, The New England journal of medicine.

[18]  J. Reis-Filho,et al.  Bi‐allelic alterations in DNA repair genes underpin homologous recombination DNA repair defects in breast cancer , 2017, The Journal of pathology.

[19]  Sandro Morganella,et al.  Mutational Signatures in Breast Cancer: The Problem at the DNA Level , 2017, Clinical Cancer Research.

[20]  E. Birney,et al.  HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures , 2017, Nature Medicine.

[21]  R. Plummer,et al.  A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours , 2017, British Journal of Cancer.

[22]  Alexey Sergushichev,et al.  An algorithm for fast preranked gene set enrichment analysis using cumulative statistic calculation , 2016 .

[23]  David C. Jones,et al.  Landscape of somatic mutations in 560 breast cancer whole genome sequences , 2016, Nature.

[24]  Z. Szallasi,et al.  Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer , 2016, Clinical Cancer Research.

[25]  John M S Bartlett,et al.  Abstract P1-01-01: Analytical validation of a standardized scoring protocol for Ki67: Phase-3 of an international multicenter collaboration , 2016 .

[26]  Jorge S. Reis-Filho,et al.  Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer , 2015, Science Translational Medicine.

[27]  Mårten Fernö,et al.  Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease , 2015, EMBO molecular medicine.

[28]  James M Ford,et al.  Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  E. Winer,et al.  TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Ash A. Alizadeh,et al.  Robust enumeration of cell subsets from tissue expression profiles , 2015, Nature Methods.

[31]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[32]  Paul Theodor Pyl,et al.  HTSeq—a Python framework to work with high-throughput sequencing data , 2014, bioRxiv.

[33]  A. Sieuwerts,et al.  Functional Ex Vivo Assay to Select Homologous Recombination–Deficient Breast Tumors for PARP Inhibitor Treatment , 2014, Clinical Cancer Research.

[34]  A. Tutt,et al.  Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers , 2014, Breast Cancer Research.

[35]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[36]  A. Vincent-Salomon,et al.  Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. , 2012, Cancer research.

[37]  G. Mills,et al.  Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer , 2012, British Journal of Cancer.

[38]  A. Børresen-Dale,et al.  Mutational Processes Molding the Genomes of 21 Breast Cancers , 2012, Cell.

[39]  Z. Szallasi,et al.  Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. , 2012, Cancer discovery.

[40]  Xi Chen,et al.  TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer , 2012, Cancer informatics.

[41]  S. Salzberg,et al.  FLASH: fast length adjustment of short reads to improve genome assemblies , 2011, Bioinform..

[42]  H. Mackay,et al.  Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. , 2011, The Lancet. Oncology.

[43]  A. Ashworth,et al.  A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer , 2010, Clinical Cancer Research.

[44]  M. Dowsett,et al.  Proliferation and Apoptosis as Markers of Benefit in Neoadjuvant Endocrine Therapy of Breast Cancer , 2006, Clinical Cancer Research.

[45]  Thomas Helleday,et al.  Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase , 2005, Nature.

[46]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[47]  M. Dowsett,et al.  Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  C. Osborne,et al.  Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  S. Vispé,et al.  Overexpression of Rad51 protein stimulates homologous recombination and increases resistance of mammalian cells to ionizing radiation. , 1998, Nucleic acids research.

[50]  N. Kamada,et al.  S phase specific formation of the human Rad51 protein nuclear foci in lymphocytes. , 1996, Oncogene.

[51]  John N. Hutchinson,et al.  Interferon Signaling is Diminished with Age and is Associated with Immune Checkpoint Blockade Efficacy in Triple-Negative Breast Cancer. , 2019, Cancer discovery.

[52]  N. Rosenfeld,et al.  Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[53]  M. Robson,et al.  Olaparib for Metastatic Germline BRCA-Mutated Breast Cancer. , 2017, The New England journal of medicine.

[54]  Anne Floquet,et al.  Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. , 2017, The Lancet. Oncology.

[55]  M. Hallett,et al.  Absolute assignment of breast cancer intrinsic molecular subtype. , 2015, Journal of the National Cancer Institute.

[56]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..

[57]  Wolf-Dietrich Heyer,et al.  Homologous recombination in DNA repair and DNA damage tolerance , 2008, Cell Research.